Lesson plan
VU0530244
VU0530244 is a potent, selective, and putatively peripherally restricted serotonin 5-HT 2B receptor antagonist which was first described in 2023. Another similar drug, VU0631019, was also described alongside VU0530244. They were identified via high-throughput screening (HTS). The affinity ( ) of VU0530244 for the serotonin 5-HT 2B receptor was found to be 17.3 nM. Its affinity ( ) values at the serotonin 5-HT 2A and 5-HT 2C receptors were greater than 10,000 nM (>578-fold less than for the serotonin 5-HT 2B receptor). The drug is predicted to be a robust P-glycoprotein substrate and hence is expected to have very limited blood–brain barrier permeability. Serotonin 5-HT 2B receptor antagonists are of interest for potential use in medicine to treat pulmonary arterial hypertension, valvular heart disease, and related cardiopathies. However, reduced serotonin 5-HT 2B receptor signaling in the central nervous system has been linked to adverse effects such as impulsivity, suicidality, and sleep disturbances, among others. Such potential side effects can be avoided with the use of peripherally restricted serotonin 5-HT 2B receptor antagonists.…
Article summary
VU0530244 is a potent, selective, and putatively peripherally restricted serotonin 5-HT 2B receptor antagonist which was first described in 2023. Another similar drug, VU0631019, was also described alongside VU0530244. They were identified via high-throughput screening (HTS). The affinity ( ) of VU0530244 for the serotonin 5-HT 2B receptor was found to be 17.3 nM. Its affinity ( ) values at the serotonin 5-HT 2A and 5-HT 2C receptors were greater than 10,000 nM (>578-fold less than for the serotonin 5-HT 2B receptor). The drug is predicted to be a robust P-glycoprotein substrate and hence is expected to have very limited blood–brain barrier permeability. Serotonin 5-HT 2B receptor antagonists are of interest for potential use in medicine to treat pulmonary arterial hypertension, valvular heart disease, and related cardiopathies. However, reduced serotonin 5-HT 2B receptor signaling in the central nervous system has been linked to adverse effects such as impulsivity, suicidality, and sleep disturbances, among others. Such potential side effects can be avoided with the use of peripherally restricted serotonin 5-HT 2B receptor antagonists.…
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.